TMCnet News
IDEXX Expands SNAP Platform with Leish 4Dx Test to Support Veterinarians Globally in Diagnosing Vector-borne DiseasesThe rapid diagnostic test provides a comprehensive solution for detecting canine leishmaniosis that impacts one in 10 dogs in endemic regions WESTBROOK, Maine, Nov. 8, 2023 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announced the upcoming launch of the SNAP® Leish 4Dx® Test, a comprehensive screening test for vector-borne diseases, including canine leishmaniosis. The SNAP Leish 4Dx Test uses the trusted SNAP 4Dx Plus testing platform, which detects Lyme disease, heartworm disease, ehrlichiosis, and anaplasmosis. By replacing Lyme disease detection with detection of leishmaniosis, a more prevalent endemic disease in certain regions of the world, the SNAP Leish 4Dx Test supports vector-borne disease diagnosis globally. The test will be available in Europe and Asia beginning February 2024. Leishmaniosis is a potentially fatal zoonotic disease transmitted to dogs by sand flies commonly found in tropical and subtropical regions of Europe, Asia, Africa, and South and Central America. Early detection is key; any dog living in or traveling to these endemic regions is susceptible to infection and should be tested, as the disease can be fatal if left untreated. Infected dogs can remain asymptomatic for months to years, making testing for leishmaniosis an essential component of annual wellness screens. "In Leishmania-endemic areas globally, where one in 10 dogs tested may be positive, it's critical for practitioners to screen healthy dogs annually for Leishmania antibodies, along with other common vector-borne pathogens, using a qualitative, comprehensive test with sufficient sensitivity and specificity at the point-of-care," said Professor Guadalupe Miró, DEVPC, Veterinary Faculty, Universidad Complutense of Madrid, Spain. "For Leishmania-seropositive dogs, it's also extremely important to quantify infection level and consider results from chemistry, CBC differentials, and urinalysis, so veterinarians can best determine a treatment or monitoring pan." The launch of the SNAP Leish 4Dx Test provides veterinarians with an end-to-end solution for vector-borne disease testing, including:
"Parasites and vector-borne diseases like leishmaniosis are an increasing risk to the health of pets globally," said Jay Mazelsky, IDEXX President and Chief Executive Officer. "This expansion of our SNAP franchise demonstrates our commitment to expanding our vector-borne disease offering to support veterinarians worldwide in their mission to deliver a higher standard of care for pets." For more information about the SNAP platform, please visit idexx.com/en/veterinary/products/snap-tests/ About IDEXX Note Regarding Forward-Looking Statements
View original content to download multimedia:https://www.prnewswire.com/news-releases/idexx-expands-snap-platform-with-leish-4dx-test-to-support-veterinarians-globally-in-diagnosing-vector-borne-diseases-301978168.html SOURCE IDEXX Laboratories, Inc. |